• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.比较改善心肌梗死后药物依从性的干预措施的成本效益。
Health Serv Res. 2012 Dec;47(6):2097-117. doi: 10.1111/j.1475-6773.2012.01462.x. Epub 2012 Sep 21.
2
Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.在英国使用复方制剂提高依从性对继发性心血管疾病预防的成本效益及公共卫生效益
BMJ Open. 2015 May 9;5(5):e007111. doi: 10.1136/bmjopen-2014-007111.
3
Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.心血管复方制剂在西班牙二级预防患者治疗中的效用:一项成本效益研究。
Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):42-49. doi: 10.1016/j.rec.2016.05.009. Epub 2016 Jul 26.
4
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.复方制剂用于心肌梗死和中风一级预防的成本效益分析。
Eur J Epidemiol. 2016 Apr;31(4):415-26. doi: 10.1007/s10654-016-0122-1. Epub 2016 Mar 5.
5
Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction.心肌梗死后提供预防性药物全面覆盖的长期成本效益
Circ Cardiovasc Qual Outcomes. 2015 May;8(3):252-9. doi: 10.1161/CIRCOUTCOMES.114.001330. Epub 2015 May 5.
6
Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.固定剂量复方制剂在中国、印度、墨西哥、尼日利亚和南非用于心血管疾病二级预防的成本效益:一项建模研究。
Lancet Glob Health. 2019 Oct;7(10):e1346-e1358. doi: 10.1016/S2214-109X(19)30339-0. Epub 2019 Aug 30.
7
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.为提高心肌梗死后医疗保险受益人的药物依从性而提供全面药物覆盖的成本效益。
Circulation. 2008 Mar 11;117(10):1261-8. doi: 10.1161/CIRCULATIONAHA.107.735605. Epub 2008 Feb 19.
8
Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.对心血管疾病高危人群使用复方制剂与常规护理或最佳预防措施进行成本效益分析。
PLoS One. 2017 Sep 5;12(9):e0182625. doi: 10.1371/journal.pone.0182625. eCollection 2017.
9
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.卡那奴单抗预防复发性心血管事件的成本效益分析。
JAMA Cardiol. 2019 Feb 1;4(2):128-135. doi: 10.1001/jamacardio.2018.4566.
10
A polypill strategy to improve adherence: results from the FOCUS project.多药复方片策略提高依从性:FOCUS 项目结果。
J Am Coll Cardiol. 2014;64(20):2071-82. doi: 10.1016/j.jacc.2014.08.021. Epub 2014 Sep 1.

引用本文的文献

1
Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study.降脂治疗的心血管疾病患者最佳药物依从性的预期成本节约:一项多国经济评估研究。
J Am Heart Assoc. 2024 Nov 19;13(22):e037792. doi: 10.1161/JAHA.124.037792. Epub 2024 Nov 15.
2
A systematic review of the theory of planned behaviour interventions for chronic diseases in low health-literacy settings.低健康素养环境下针对慢性病的计划行为理论干预措施的系统评价。
J Glob Health. 2023 Sep 8;13:04079. doi: 10.7189/jogh.13.04079.
3
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.在葡萄牙心血管和脑血管疾病二级预防中,与单一成分药物分别使用相比,CNIC复方药丸策略的成本效益:MERCURY研究
J Health Econ Outcomes Res. 2022 Nov 22;9(2):134-146. doi: 10.36469/001c.39768. eCollection 2022.
4
Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.固定剂量复方制剂(波利维)在心血管疾病一级和二级预防中的成本效益:系统文献回顾。
PLoS One. 2022 Jul 28;17(7):e0271908. doi: 10.1371/journal.pone.0271908. eCollection 2022.
5
Are patients more adherent to newer drugs?患者对新药的依从性更高吗?
Health Care Manag Sci. 2020 Dec;23(4):605-618. doi: 10.1007/s10729-020-09513-5. Epub 2020 Aug 8.
6
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.新型心血管疾病二级预防治疗策略:成本效益的系统评价
Pharmacoeconomics. 2020 Oct;38(10):1095-1113. doi: 10.1007/s40273-020-00936-0.
7
Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial.干预措施支持心肌梗死后长期坚持并减少心血管事件(ISLAND):实用随机对照试验。
BMJ. 2020 Jun 10;369:m1731. doi: 10.1136/bmj.m1731.
8
Developing Behavior Change Interventions for Self-Management in Chronic Illness: An Integrative Overview.为慢性病自我管理制定行为改变干预措施:综合概述
Eur Psychol. 2019;24(1):7-25. doi: 10.1027/1016-9040/a000330. Epub 2018 Aug 16.
9
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial.通过常规治疗中添加抗动脉粥样硬化药物实现卒中最小化(SMAART):一项随机对照试验的研究方案
Trials. 2018 Mar 14;19(1):181. doi: 10.1186/s13063-018-2564-0.
10
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.用于预防动脉粥样硬化性心血管疾病的固定剂量联合疗法。
Cochrane Database Syst Rev. 2017 Mar 6;3(3):CD009868. doi: 10.1002/14651858.CD009868.pub3.

本文引用的文献

1
Targeting cardiovascular medication adherence interventions.针对心血管药物治疗依从性干预措施。
J Am Pharm Assoc (2003). 2012 May-Jun;52(3):381-97. doi: 10.1331/JAPhA.2012.10211.
2
Patient education in the management of coronary heart disease.冠心病管理中的患者教育
Cochrane Database Syst Rev. 2011 Dec 7(12):CD008895. doi: 10.1002/14651858.CD008895.pub2.
3
The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.固定剂量复方药物用于二级心血管预防项目:使用固定剂量复方药物改善二级心血管预防的公平可及性和依从性。研究设计和目标。
Am Heart J. 2011 Nov;162(5):811-817.e1. doi: 10.1016/j.ahj.2011.08.012.
4
Full coverage for preventive medications after myocardial infarction.心肌梗死后的预防性药物全覆盖。
N Engl J Med. 2011 Dec 1;365(22):2088-97. doi: 10.1056/NEJMsa1107913. Epub 2011 Nov 14.
5
Results of the Medicare Health Support disease-management pilot program.医疗保险健康支持疾病管理试点计划的结果。
N Engl J Med. 2011 Nov 3;365(18):1704-12. doi: 10.1056/NEJMsa1011785.
6
Imaging studies for low back pain.腰痛的影像学检查
J Pain Palliat Care Pharmacother. 2008;22(4):306-11. doi: 10.1080/15360280802537332.
7
The implications of therapeutic complexity on adherence to cardiovascular medications.治疗复杂性对心血管药物依从性的影响。
Arch Intern Med. 2011 May 9;171(9):814-22. doi: 10.1001/archinternmed.2010.495.
8
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects.美国成年人中使用复方药丸的预期影响:药物使用、心血管风险降低和副作用。
Am Heart J. 2011 Apr;161(4):719-25. doi: 10.1016/j.ahj.2010.12.019.
9
The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.C 反应蛋白检测和瑞舒伐他汀治疗对胆固醇水平正常患者的成本效益分析。
J Am Coll Cardiol. 2011 Feb 15;57(7):784-91. doi: 10.1016/j.jacc.2010.07.059.
10
Heart disease and stroke statistics--2011 update: a report from the American Heart Association.心脏病和中风统计数据--2011 年更新:来自美国心脏协会的报告。
Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15.

比较改善心肌梗死后药物依从性的干预措施的成本效益。

Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.

机构信息

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA.

出版信息

Health Serv Res. 2012 Dec;47(6):2097-117. doi: 10.1111/j.1475-6773.2012.01462.x. Epub 2012 Sep 21.

DOI:10.1111/j.1475-6773.2012.01462.x
PMID:22998129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3523366/
Abstract

OBJECTIVE

To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.

DATA SOURCES/STUDY SETTING: Cost-effectiveness analysis.

STUDY DESIGN

We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.

DATA COLLECTION/EXTRACTION METHODS: Model inputs were extracted from published literature.

PRINCIPAL FINDINGS

Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.

CONCLUSIONS

Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.

摘要

目的

评估改善心肌梗死后(MI)患者依从性的干预措施的比较成本效益。

数据来源/研究范围:成本效益分析。

研究设计

我们开发了一个马尔可夫模型,模拟了一组假定的 65 岁 MI 后患者的队列,这些患者被开了二级预防药物。我们评估了邮寄教育、疾病管理、多药联合治疗以及这些干预措施的组合。分析从全社会角度在终生范围内进行。主要结果是增量成本效益比(ICER),以每获得质量调整生命年(QALY)的成本来衡量。

数据收集/提取方法:模型输入从已发表的文献中提取。

主要发现

与常规护理相比,只有邮寄教育在改善健康结果的同时还降低了成本。邮寄教育加疾病管理、疾病管理、多药联合治疗、邮寄教育加多药联合治疗和疾病管理加多药联合治疗的成本分别为每获得一个 QALY 增加 74600 美元、69200 美元、133000 美元、113000 美元和 142900 美元。在增量分析中,只有邮寄教育的 ICER 低于 100000 美元/ QALY,因此是最佳策略。多药联合治疗,特别是与邮寄教育联合使用时,如果价格降至每月 100 美元以下,可能具有成本效益,并且具有潜在的成本节约效果。

结论

邮寄教育和多药联合治疗,一旦可用,可能是改善 MI 后药物依从性的节省成本策略。